Literature DB >> 12322710

Developmental onset of polysaccharide storage myopathy in 4 Quarter Horse foals.

Flavio D De La Corte1, Stephanie J Valberg, Jennifer M MacLeay, James R Mickelson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12322710     DOI: 10.1892/0891-6640(2002)016<0581:doopsm>2.3.co;2

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


× No keyword cloud information.
  6 in total

1.  Glycogen synthase (GYS1) mutation causes a novel skeletal muscle glycogenosis.

Authors:  Molly E McCue; Stephanie J Valberg; Michael B Miller; Claire Wade; Salvatore DiMauro; Hasan O Akman; James R Mickelson
Journal:  Genomics       Date:  2008-03-20       Impact factor: 5.736

2.  Clinical and histopathological features of myofibrillar myopathy in Warmblood horses.

Authors:  S J Valberg; A M Nicholson; S S Lewis; R A Reardon; C J Finno
Journal:  Equine Vet J       Date:  2017-06-26       Impact factor: 2.888

3.  Suspected congenital centronuclear myopathy in an Arabian-cross foal.

Authors:  F Polle; F M Andrews; T Gillon; S C Eades; R S McConnico; G M Strain; S J Valberg; L T Guo; G D Shelton
Journal:  J Vet Intern Med       Date:  2014 Nov-Dec       Impact factor: 3.333

4.  White muscle disease in foals: focus on selenium soil content. A case series.

Authors:  Catherine Delesalle; Marco de Bruijn; Sanne Wilmink; Hilde Vandendriessche; Gerben Mol; Berit Boshuizen; Lukas Plancke; Guy Grinwis
Journal:  BMC Vet Res       Date:  2017-05-03       Impact factor: 2.741

5.  Metabolic disorders in foals.

Authors:  K T T Corley
Journal:  Equine Vet Educ       Date:  2012-02-20       Impact factor: 1.063

6.  Allele copy number and underlying pathology are associated with subclinical severity in equine type 1 polysaccharide storage myopathy (PSSM1).

Authors:  Rosie J Naylor; Leanda Livesey; John Schumacher; Nicole Henke; Claire Massey; Kenny V Brock; Marta Fernandez-Fuente; Richard J Piercy
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.